Treatment for Renal Masses

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Princess Margaret Cancer Centre, Toronto, Canada
Renal Masses
Eligibility
18+
All Sexes
Eligible conditions
Select

Study Summary

Comparison of OpeN VErsus RoboTic Partial Nephrectomy

See full description

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Renal Masses

Study Objectives

This trial is evaluating whether Treatment will improve 4 primary outcomes and 13 secondary outcomes in patients with Renal Masses. Measurement will happen over the course of Duration of surgery.

1-3 weeks post-operatively
Margin size
Positive margin rate
1-7 days
Length of Stay
Month 6
Surgical Recovery/Flank Bulge
Duration of surgery
Blood Loss
Conversion rate to radical nephrectomy or open partial nephrectomy
Operative Time
Warm Ischemia Time
Study duration (2 years)
Health Economics
Recruitment Potential
Resource Utilization - Cost of Study Participation
Resource Utilization - Operating Room/Robotic Studio Time Availability
Suitability of measures
Month 6
Analgesic Requirements
Quality of Life: EORTC QLQ-C30
Month 6
Complication Rates
Renal Function

Trial Safety

Safety Progress

1 of 3

Other trials for Renal Masses

Trial Design

2 Treatment Groups

Robotic Partial Nephrectomy
1 of 2
Open Partial Nephrectomy
1 of 2
Active Control

This trial requires 30 total participants across 2 different treatment groups

This trial involves 2 different treatments. Treatment is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.

Robotic Partial Nephrectomy
Procedure
Partial nephrectomy performed using the DaVinci robotic surgical system.
Open Partial Nephrectomy
Procedure
Partial nephrectomy performed using the open approach.

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: study duration (2 years)
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly study duration (2 years) for reporting.

Closest Location

Princess Margaret Cancer Centre - Toronto, Canada

Eligibility Criteria

This trial is for patients born any sex aged 18 and older. There are 5 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
Radiologically characterized T1 renal mass
Elected for partial nephrectomy surgery
Under the care of a uro-oncologist at Princess Margaret Cancer Centre
Willing to comply with follow-up protocol
Capable of providing informed consent

Patient Q&A Section

Ask a question about the study

Other questions from users

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any geographic restrictions to consider when applying for this trial?

Patients from any state can participate in this trial, so long as they are able to attend all treatment sessions.

Will my insurance cover participating in this trial?

In order to understand how insurance coverage works for this trial, you will need to contact the study coordinator.

See if you qualify for this trial
Get access to this novel treatment for Renal Masses by sharing your contact details with the study coordinator.